Compare PNRG & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PNRG | CMPX |
|---|---|---|
| Founded | 1973 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 344.8M | 408.8M |
| IPO Year | 1995 | 2020 |
| Metric | PNRG | CMPX |
|---|---|---|
| Price | $217.35 | $2.38 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 9 |
| Target Price | ★ $160.00 | $14.57 |
| AVG Volume (30 Days) | 72.8K | ★ 2.9M |
| Earning Date | 04-16-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 4.57 | N/A |
| Revenue | ★ $189,052,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $18.18 | $934.41 |
| P/E Ratio | $47.09 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $126.40 | $1.61 |
| 52 Week High | $278.90 | $6.88 |
| Indicator | PNRG | CMPX |
|---|---|---|
| Relative Strength Index (RSI) | 64.80 | 52.79 |
| Support Level | $202.23 | $1.82 |
| Resistance Level | $227.63 | $2.51 |
| Average True Range (ATR) | 10.50 | 0.13 |
| MACD | 0.27 | -0.01 |
| Stochastic Oscillator | 57.39 | 45.71 |
PrimeEnergy Resources Corp is an independent oil and natural gas company that is engaged in acquiring, developing, and producing oil and natural gas. It owns producing and non-producing properties located in Texas and Oklahoma. The company's business activities include development and exploratory drilling and providing well servicing support operations for many of the onshore oil and gas wells through its subsidiaries. It is also active in the acquisition of producing oil and gas properties through joint ventures with industry partners.
Compass Therapeutics Inc is a clinical-stage oncology-focused biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to target the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-A, Bispecific, and CTX-8371.